Stokes, Ashley M.

AbstractPurposePerfusion MRI reveals important tumor physiological and pathophysiologic information, making it a critical component in managing brain tumor patients. This study aimed to develop a dual‐echo 3D spiral technique with a single‐bolus scheme to simultaneously acquire both dynamic susceptibility contrast (DSC) and dynamic contrast‐enhanced (DCE) data and overcome the limitations of current EPI‐based techniques.MethodsA 3D spiral‐based technique with dual‐echo acquisition was implemented and optimized on a 3T MRI scanner with a spiral staircase trajectory and through‐plane SENSE acceleration for improved speed and image quality, in‐plane variable‐density undersampling combined with a sliding‐window acquisition and reconstruction approach for increased speed, and an advanced iterative deblurring algorithm. Four volunteers were scanned and compared with the standard of care (SOC) single‐echo EPI and a dual‐echo EPI technique. Two patients were scanned with the spiral technique during a preload bolus and compared with the SOC single‐echo EPI collected during the second bolus injection.ResultsVolunteer data demonstrated that the spiral technique achieved high image quality, reduced geometric artifacts, and high temporal SNR compared with both single‐echo and dual‐echo EPI. Patient perfusion data showed that the spiral acquisition achieved accurate DSC quantification comparable to SOC single‐echo dual‐dose EPI, with the additional DCE information.ConclusionA 3D dual‐echo spiral technique was developed to simultaneously acquire both DSC and DCE data in a single‐bolus injection with reduced contrast use. Preliminary volunteer and patient data demonstrated increased temporal SNR, reduced geometric artifacts, and accurate perfusion quantification, suggesting a competitive alternative to SOC‐EPI techniques for brain perfusion MRI.

AbstractPurpose has often been proposed as a quantitative imaging biomarker for diagnosis, prognosis, and treatment response assessment for various tumors. None of the many software tools for quantification are standardized. The ISMRM Open Science Initiative for Perfusion Imaging–Dynamic Contrast‐Enhanced (OSIPI‐DCE) challenge was designed to benchmark methods to better help the efforts to standardize measurement.MethodsA framework was created to evaluate values produced by DCE‐MRI analysis pipelines to enable benchmarking. The perfusion MRI community was invited to apply their pipelines for quantification in glioblastoma from clinical and synthetic patients. Submissions were required to include the entrants' values, the applied software, and a standard operating procedure. These were evaluated using the proposed score defined with accuracy, repeatability, and reproducibility components.ResultsAcross the 10 received submissions, the score ranged from 28% to 78% with a 59% median. The accuracy, repeatability, and reproducibility scores ranged from 0.54 to 0.92, 0.64 to 0.86, and 0.65 to 1.00, respectively (0–1 = lowest–highest). Manual arterial input function selection markedly affected the reproducibility and showed greater variability in analysis than automated methods. Furthermore, provision of a detailed standard operating procedure was critical for higher reproducibility.ConclusionsThis study reports results from the OSIPI‐DCE challenge and highlights the high inter‐software variability within estimation, providing a framework for ongoing benchmarking against the scores presented. Through this challenge, the participating teams were ranked based on the performance of their software tools in the particular setting of this challenge. In a real‐world clinical setting, many of these tools may perform differently with different benchmarking methodology.

Abstract INTRODUCTION Differentiation of glioblastoma recurrence from post treatment radiation effects (PTRE) would improve patient management. Dynamic susceptibility contrast (DSC) MRI can be used to generate fractional tumor burden (FTB) maps, via application of regional cerebral blood volume (RCBV) thresholds, to spatially differentiate recurrence from PTRE. FTB maps derived from a DSC-MRI protocol that includes a contrast agent preload in addition to the bolus injection and a moderate-flip angle (MFA) been histologically validated. Recently, a single-dose, low-flip angle (LFA) protocol was shown to provide RCBV measurements consistent with the MFA protocol and has been recommended as a consensus protocol. This study aims to identify the RCBV thresholds for the single-dose, LFA protocol that generates FTB maps, concordant with those obtained from the reference double-dose, MFA protocol. METHODS Two sets of DSC-MRI data were collected sequentially from 52 patients using a single-dose, low-flip angle (30o) protocol and a double-dose, moderate flip angle (60o) protocol using TR = 1.5s and TE = 30ms. Standardized RCBV maps (sRCBV) were obtained and co-registered with the post-contrast T1-weighted images using the FDA-approved clinical software, IB Neuro™ and IB Delta Suite™, respectively. The ground truth MFA-based FTB maps were computed using multiple sRCBV thresholds (1.0 and 1.75). An ROC analysis was conducted to identify the optimal, voxel-wise LFA sRCBV thresholds to produce FTB maps that best match the reference maps. RESULTS/ CONCLUSIONS The ROC analysis identified a lower LFA threshold of 1.0 to accurately distinguish PTRE from tumor recurrence and an upper threshold of 1.55 to differentiate aggressive tumor regions. The single-dose, LFA protocol eliminates variations in the contrast agent incubation time between the preload and bolus injection. This study provides motivation for the use of the single-dose LFA protocol in the management of patients with glioblastoma and is a reliable method for distinguishing tumor from PTRE.

BackgroundAdvanced diffusion‐based MRI biomarkers may provide insight into microstructural and perfusion changes associated with neurodegeneration and cognitive decline.PurposeTo assess longitudinal microstructural and perfusion changes using apparent diffusion coefficient (ADC) and intravoxel incoherent motion diffusion‐weighted imaging (IVIM‐DWI) parameters in cognitively impaired (CI) and healthy control (HC) groups.Study TypeProspective/longitudinal.PopulationTwelve CI patients (75% female) and 13 HC subjects (69% female).Field Strength/Sequence3 T; Spin‐Echo‐IVIM‐DWI.AssessmentTwo MRI scans were performed with a 12‐month interval. ADC and IVIM‐DWI metrics (diffusion coefficient [D] and perfusion fraction [f]) were generated from monoexponential and biexponential fits, respectively. Additionally, voxel‐based correlations were evaluated between change in Montreal Cognitive Assessment (ΔMoCA) and baseline imaging parameters.Statistical TestsAnalysis of covariance with sex and age as covariates was performed for main effects of group and time (false discovery rate [FDR] corrected) with post hoc comparisons using Bonferroni correction. Partial‐η2 and Hedges' g were used for effect‐size analysis. Spearman's correlations (FDR corrected) were used for the relationship between ΔMoCA score and imaging. P < 0.05 was considered statistically significant.ResultsSignificant differences were found for the main effects of group (HC vs. CI) and time. For group effects, higher ADC, IVIM‐D, and IVIM‐f were observed in the CI group compared to HC (ADC: 1.23 ± 0.08.10−3 vs. 1.09 ± 0.07.10−3 mm2/sec; IVIM‐D: 0.82 ± 0.01.10−3 vs. 0.73 ± 0.01.10−3 mm2/sec; and IVIM‐f: 0.317 ± 0.008 vs. 0.253 ± 0.009). Significantly higher ADC, IVIM‐D, and IVIM‐f values were observed in the CI group after 12 months (ADC: 1.45 ± 0.05.10−3 vs. 1.50 ± 0.07.10−3 mm2/sec; IVIM‐D: 0.87 ± 0.01.10−3 vs. 0.94 ± 0.02.10−3 mm2/sec; and IVIM‐f: 0.303 ± 0.007 vs. 0.332 ± 0.008), but not in the HC group at large effect size. ADC, IVIM‐D, and IVIM‐f negatively correlated with ΔMoCA score (ρ = −0.49, −0.51, and −0.50, respectively).Data ConclusionThese findings demonstrate that longitudinal differences between CI and HC cohorts can be measured using IVIM‐based metrics.Level of Evidence2Technical Efficacy Stage2

Relative cerebral blood volume (rCBV) obtained from dynamic susceptibility contrast (DSC) MRI is adversely impacted by contrast agent leakage in brain tumors. Using simulations, we previously demonstrated that multi-echo DSC-MRI protocols provide improvements in contrast agent dosing, pulse sequence flexibility, and rCBV accuracy. The purpose of this study is to assess the in-vivo performance of dual-echo acquisitions in patients with brain tumors (n = 59). To verify pulse sequence flexibility, four single-dose dual-echo acquisitions were tested with variations in contrast agent dose, flip angle, and repetition time, and the resulting dual-echo rCBV was compared to standard single-echo rCBV obtained with preload (double-dose). Dual-echo rCBV was comparable to standard double-dose single-echo protocols (mean (standard deviation) tumor rCBV 2.17 (1.28) vs. 2.06 (1.20), respectively). High rCBV similarity was observed (CCC = 0.96), which was maintained across both flip angle (CCC = 0.98) and repetition time (CCC = 0.96) permutations, demonstrating that dual-echo acquisitions provide flexibility in acquisition parameters. Furthermore, a single dual-echo acquisition was shown to enable quantification of both perfusion and permeability metrics. In conclusion, single-dose dual-echo acquisitions provide similar rCBV to standard double-dose single-echo acquisitions, suggesting contrast agent dose can be reduced while providing significant pulse sequence flexibility and complementary tumor perfusion and permeability metrics.

PurposeThe purpose of this study was to develop a spiral‐based combined spin‐ and gradient‐echo (spiral‐SAGE) method for simultaneous dynamic contrast‐enhanced (DCE‐MRI) and dynamic susceptibility contrast MRI (DSC‐MRI).MethodsUsing this sequence, we obtained gradient‐echo TEs of 1.69 and 26 ms, a SE TE of 87.72 ms, with a TR of 1663 ms. Using an iterative SENSE reconstruction followed by deblurring, spiral‐induced image artifacts were minimized. Healthy volunteer images are shown to demonstrate image quality using the optimized reconstruction, as well as for comparison with EPI‐based SAGE. A bioreactor phantom was used to compare dynamic‐contrast time courses with both spiral‐SAGE and EPI‐SAGE. A proof‐of‐concept cohort of patients with brain tumors shows the range of hemodynamic maps available using spiral‐SAGE.ResultsComparison of spiral‐SAGE images with conventional EPI‐SAGE images illustrates substantial reductions of image distortion and artifactual image intensity variations. Bioreactor phantom data show similar dynamic contrast time courses between standard EPI‐SAGE and spiral‐SAGE for the second and third echoes, whereas first‐echo data show improvements in quantifying T1 changes with shorter echo times. In a cohort of patients with brain tumors, spiral‐SAGE–based perfusion and permeability maps are shown with comparison with the standard single‐echo EPI perfusion map.ConclusionSpiral‐SAGE provides a substantial improvement for the assessment of perfusion and permeability by mitigating artifacts typically encountered with EPI and by providing a shorter echo time for improved characterization of permeability. Spiral‐SAGE enables quantification of perfusion, permeability, and vessel architectural parameters, as demonstrated in brain tumors.

BackgroundAlzheimer's disease (AD) is a progressive neurodegenerative disease that affects aging populations. Current MRI techniques are often limited in their sensitivity to underlying neuropathological changes.PurposeTo characterize differences in voxel‐based morphometry (VBM), apparent diffusion coefficient (ADC), and intravoxel incoherent motion diffusion‐weighted imaging (IVIM‐DWI) metrics in aging populations. Additionally, to investigate the connection between cognitive assessments and neuroimaging metrics.Study TypeProspective/cross‐sectional.PopulationIn all, 49 subjects, including 13 with AD dementia, 12 with mild cognitive impairment (MCI), and 24 healthy controls (HC).Field Strength/Sequence3T/magnetization‐prepared rapid acquisition gradient echo (MP‐RAGE) and IVIM‐DWIAssessmentAll participants completed a cognitive screening battery prior to MRI. IVIM‐DWI maps (pure diffusion coefficient [D], pseudodiffusion coefficient [D*], and perfusion fraction [f]) were generated from a biexponential fit of diffusion MRI data. VBM was performed on the standard T1‐weighted MP‐RAGE structural images. Group‐wise templates were used to compare across groups.Statistical TestsAnalysis of covariance (ANCOVA) with gender and age as covariates (familywise error [FWE] corrected, post‐hoc comparisons using Bonferroni correction) for group comparisons. Partial‐η2 and Hedges' g were used for effect‐size analysis. Spearman's correlations (false discovery rate [FDR]‐corrected) for the relationship between cognitive scores and imaging.ResultsClusters of significant group‐wise differences were found mainly in the temporal lobe, hippocampus, and amygdala using all VBM and IVIM methods (P < 0.05 FWE). While VBM showed significant changes between MCI and AD groups and between HC and AD groups, no significant clusters were observed between HC and MCI using VBM. ADC and IVIM‐D demonstrated significant changes, at P < 0.05 FWE, between HC and MCI, notably in the amygdala and hippocampus. Several voxel‐based correlations were observed between neuroimaging metrics and cognitive tests within the cognitively impaired groups (P < 0.05 FDR).Data ConclusionThese findings suggest that IVIM‐DWI metrics may be earlier biomarkers for AD‐related changes than VBM. The use of these techniques may provide novel insight into subvoxel neurodegenerative processes.Level of Evidence2Technical Efficacy Stage2 J. MAGN. RESON. IMAGING 2020;52:1811–1826.

Abstract INTRODUCTION Neuroimaging dogma for glioblastoma asserts that hyperintensity on T1Gd MRI reveals the bulk of the tumor, while T2/FLAIR signal indicates edema. However, it is unclear whether this edema results from immune response or increased tumor cells. Further, one significant driver of the known sex differences in glioblastoma may be differences in immune response, due to the X-linkage of many immune genes. Based on this, we hypothesized that assumptions regarding tumor cellularity in T2/FLAIR images should be tailored to the biological sex of the patient. METHODS Using a retrospective cohort of 18 primary glioblastoma patients receiving multiple image-localized biopsies (82 total) and standard MRI, we assessed: distance of biopsy from T1Gd and T2 areas; a pathologist’s score of percent tumor cell density; and an imaging-based invasion metric, D/ρ. This metric is derived from the biomathematical Proliferation-Invasion model of glioma growth, which features two parameters, net growth rate (ρ) and net invasion rate (D). Their ratio D/ρ is related to degree of invasion, and is estimated from volumetric measurements of MRI abnormalities. Additionally, 25 patient-derived xenograft models implanted in females were grown until moribund, at which point brains were excised and stained for DAPI (to show all cells) and Lamin (to highlight tumor cells). Image processing of lamin-stained sections defines contours of intensity correlating with cell density. RESULTS Outside both the T1Gd and T2 region, male patient biopsies had higher tumor cell densities than females. Males also tended to have higher invasion metrics. Although each set derived from different patients, preclinical metrics of invasion were positively correlated with clinical invasion in females but negatively correlated in males. CONCLUSION Our preliminary finding that cell distribution patterns correlate with imaging metrics differently between the sexes supports the hypothesis that the degree of tumor cell density represented on certain MRI sequences may be sex-specific.

Abstract Dynamic susceptibility contrast (DSC) MRI measures of brain tumor cerebral blood volume (CBV) are able to predict grade, overall survival and response to treatment. Wide-spread acceptance of DSC-MRI has been challenged by the need to balance contrast agent dose and CBV accuracy. The goal of this study was to identify and validate single-dose, BTIP compliant, DSC-MRI protocols. Using a validated, patient-based DRO, we evaluated CBV accuracy across a range of acquisition parameters (field strength, TR, TE, flip angle, multi-echo acquisitions, dosing protocols) and post-processing steps. To validate the optimal protocols, we next collected DSC-MRI data following ASFNR’s recommended “double – dose” approach, where a single-dose preload (to minimize T1 effects) is given prior to a second bolus injection (for DSC-MRI data acquisition). The single-dose DSC-MRI data was collected during the preload bolus injection. Consistency of the derived CBV data, visual agreement and data characteristics (e.g. CNR) was statistically evaluated. When using a single-dose and routine single-echo pulse sequence, the DRO analysis found that a low flip angle (LFA = 30o) and 30ms TE provided the highest CBV accuracy (concordance correlation coefficient (CCC) = 0.92) and precision (coefficient of variation (CV) = 8.2%)). For comparison, the maximum accuracy found with the DRO utilizes a double-dose injection protocol and yielded a CCC of 0.98 and CV of 6.8%. Single-dose, multi-echo acquisitions provided higher accuracy than the LFA data and matched that found with the double-dose approach. In patients (data collection ongoing), the agreement between single-dose LFA (n > 40) or multi-echo (n > 40) based CBV values and the reference double-dose approach was very high (CCC > 0.94) and were statistically equivalent. Optimized single-dose DSC-MRI protocols provide highly accurate CBV data, use lower doses of contrast agent, and simplify scan procedures, indicating their potential for robust use in clinical practice and trials.